Bionano Genomics 

$1.32
1062
+$0.02+1.54% Today

Statistics

Day High
1.5
Day Low
1.21
52W High
5.84
52W Low
1.3
Volume
1,098,197
Avg. Volume
235,962
Mkt Cap
13.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MarExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-31.2
-20.88
-10.56
-0.24
Expected EPS
-1.355
Actual EPS
N/A

Financials

-363.98%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
61.55MRevenue
-224.03MNet Income

Analyst Ratings

$7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNGO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies that compete with Bionano's optical genome mapping solutions for complex genetic research and diagnostics.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics market space that Bionano targets.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a broad range of instruments and reagents for genomic research, including next-generation sequencing, competing with Bionano's genomic analysis technologies.
Agenus
AGEN
Mkt Cap126.5M
Agilent Technologies provides instruments, software, services, and consumables for the entire laboratory workflow, including genomics research, competing with Bionano's offerings.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen offers sample to insight solutions, including next-generation sequencing and molecular diagnostics that compete with Bionano's genomic analysis solutions.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR/Cas9 technology for genome editing, which competes indirectly with Bionano's genomic mapping and analysis technologies by offering alternative approaches to genetic research and diagnostics.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing space using CRISPR technology, offering a competitive alternative to Bionano's genomic analysis and mapping solutions.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on developing gene-based medicines using CRISPR/Cas9 technologies, indirectly competing with Bionano's genomic analysis tools by providing alternative methods for genetic research.
Twist Bioscience
TWST
Mkt Cap1.99B
Twist Bioscience operates in the synthetic biology and genomics field, producing synthetic DNA that is used in genetic research, competing with Bionano's genomic analysis and mapping technologies.

About

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Employees
98
Country
US
ISIN
US09075F4046

Listings

0 Comments

Share your thoughts

FAQ

What is Bionano Genomics stock price today?
The current price of BNGO is $1.32 USD — it has increased by +1.54% in the past 24 hours. Watch Bionano Genomics stock price performance more closely on the chart.
What is Bionano Genomics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bionano Genomics stocks are traded under the ticker BNGO.
Is Bionano Genomics stock price growing?
BNGO stock has fallen by -13.73% compared to the previous week, the month change is a -16.98% fall, over the last year Bionano Genomics has showed a -74.57% decrease.
What is Bionano Genomics market cap?
Today Bionano Genomics has the market capitalization of 13.43M
When is the next Bionano Genomics earnings date?
Bionano Genomics is going to release the next earnings report on March 05, 2026.
What were Bionano Genomics earnings last quarter?
BNGO earnings for the last quarter are -2.04 USD per share, whereas the estimation was -2.08 USD resulting in a +1.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bionano Genomics revenue for the last year?
Bionano Genomics revenue for the last year amounts to 61.55M USD.
What is Bionano Genomics net income for the last year?
BNGO net income for the last year is -224.03M USD.
How many employees does Bionano Genomics have?
As of February 02, 2026, the company has 98 employees.
In which sector is Bionano Genomics located?
Bionano Genomics operates in the Health Care sector.
When did Bionano Genomics complete a stock split?
The last stock split for Bionano Genomics was on January 27, 2025 with a ratio of 1:60.
Where is Bionano Genomics headquartered?
Bionano Genomics is headquartered in San Diego, US.